Syndax Pharmaceuticals, Inc. 宣布，其针对特发性肺纤维化（IPF）的Axatilimab二期临床试验已完成患者招募工作。这项重要研究进展为后续数据收集与分析奠定了坚实基础，公司预计将于2026年第四季度公布该项试验的关键顶线数据。
此次临床试验的顺利完成标志着Axatilimab在IPF治疗领域迈出了关键一步。作为一款创新疗法，其研究成果备受医疗界关注，有望为特发性肺纤维化患者提供新的治疗选择。
Syndax Pharmaceuticals, Inc. 宣布，其针对特发性肺纤维化（IPF）的Axatilimab二期临床试验已完成患者招募工作。这项重要研究进展为后续数据收集与分析奠定了坚实基础，公司预计将于2026年第四季度公布该项试验的关键顶线数据。
此次临床试验的顺利完成标志着Axatilimab在IPF治疗领域迈出了关键一步。作为一款创新疗法，其研究成果备受医疗界关注，有望为特发性肺纤维化患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.